These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31890731)

  • 1. Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease.
    Kang HR; Gjorgjieva M; Smith SN; Brooks ED; Chen Z; Burgess SM; Chandler RJ; Waskowicz LR; Grady KM; Li S; Mithieux G; Venditti CP; Rajas F; Koeberl DD
    Mol Ther Methods Clin Dev; 2019 Dec; 15():383-391. PubMed ID: 31890731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-α activity restored are at risk of developing hepatic tumors.
    Kim GY; Lee YM; Kwon JH; Cho JH; Pan CJ; Starost MF; Mansfield BC; Chou JY
    Mol Genet Metab; 2017 Mar; 120(3):229-234. PubMed ID: 28096054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy prevents hepatic tumor initiation in murine glycogen storage disease type Ia at the tumor-developing stage.
    Cho JH; Lee YM; Starost MF; Mansfield BC; Chou JY
    J Inherit Metab Dis; 2019 May; 42(3):459-469. PubMed ID: 30637773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal hepatic glucose-6-phosphatase-α activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia.
    Lee YM; Kim GY; Pan CJ; Mansfield BC; Chou JY
    Mol Genet Metab Rep; 2015 Jun; 3():28-32. PubMed ID: 26937391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia.
    Kang HR; Waskowicz L; Seifts AM; Landau DJ; Young SP; Koeberl DD
    Mol Ther Methods Clin Dev; 2019 Jun; 13():265-273. PubMed ID: 30859111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of hepatocellular adenoma and correction of metabolic abnormalities in murine glycogen storage disease type Ia by gene therapy.
    Lee YM; Jun HS; Pan CJ; Lin SR; Wilson LH; Mansfield BC; Chou JY
    Hepatology; 2012 Nov; 56(5):1719-29. PubMed ID: 22422504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapy using a novel G6PC-S298C variant enhances the long-term efficacy for treating glycogen storage disease type Ia.
    Zhang L; Lee C; Arnaoutova I; Anduaga J; Starost MF; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2020 Jun; 527(3):824-830. PubMed ID: 32430177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV vector-mediated reversal of hypoglycemia in canine and murine glycogen storage disease type Ia.
    Koeberl DD; Pinto C; Sun B; Li S; Kozink DM; Benjamin DK; Demaster AK; Kruse MA; Vaughn V; Hillman S; Bird A; Jackson M; Brown T; Kishnani PS; Chen YT
    Mol Ther; 2008 Apr; 16(4):665-72. PubMed ID: 18362924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic glucose-6-phosphatase-α deficiency leads to metabolic reprogramming in glycogen storage disease type Ia.
    Cho JH; Kim GY; Mansfield BC; Chou JY
    Biochem Biophys Res Commun; 2018 Apr; 498(4):925-931. PubMed ID: 29545180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.
    Landau DJ; Brooks ED; Perez-Pinera P; Amarasekara H; Mefferd A; Li S; Bird A; Gersbach CA; Koeberl DD
    Mol Ther; 2016 Apr; 24(4):697-706. PubMed ID: 26865405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.
    Lee YM; Pan CJ; Koeberl DD; Mansfield BC; Chou JY
    Mol Genet Metab; 2013 Nov; 110(3):275-80. PubMed ID: 23856420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.
    Brooks ED; Landau DJ; Everitt JI; Brown TT; Grady KM; Waskowicz L; Bass CR; D'Angelo J; Asfaw YG; Williams K; Kishnani PS; Koeberl DD
    J Inherit Metab Dis; 2018 Nov; 41(6):965-976. PubMed ID: 30043186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of tumor-promoting pathways implicated in hepatocellular adenoma/carcinoma, a long-term complication of glycogen storage disease type Ia.
    Cho JH; Lee YM; Bae SH; Chou JY
    Biochem Biophys Res Commun; 2020 Jan; 522(1):1-7. PubMed ID: 31735334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome editing using
    Arnson B; Kang HR; Brooks ED; Gheorghiu D; Ilich E; Courtney D; Everitt JI; Cullen BR; Koeberl DD
    Mol Ther Methods Clin Dev; 2023 Jun; 29():108-119. PubMed ID: 37021039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy.
    Yiu WH; Lee YM; Peng WT; Pan CJ; Mead PA; Mansfield BC; Chou JY
    Mol Ther; 2010 Jun; 18(6):1076-84. PubMed ID: 20389290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
    Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
    Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review.
    Cho JH; Weinstein DA; Lee YM
    J Inherit Metab Dis; 2021 Jan; 44(1):118-128. PubMed ID: 32474930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.
    Demaster A; Luo X; Curtis S; Williams KD; Landau DJ; Drake EJ; Kozink DM; Bird A; Crane B; Sun F; Pinto CR; Brown TT; Kemper AR; Koeberl DD
    Hum Gene Ther; 2012 Apr; 23(4):407-18. PubMed ID: 22185325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors.
    Beaty RM; Jackson M; Peterson D; Bird A; Brown T; Benjamin DK; Juopperi T; Kishnani P; Boney A; Chen YT; Koeberl DD
    Gene Ther; 2002 Aug; 9(15):1015-22. PubMed ID: 12101432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of helper-dependent adenovirus vector-mediated gene therapy in murine glycogen storage disease type Ia.
    Koeberl DD; Sun B; Bird A; Chen YT; Oka K; Chan L
    Mol Ther; 2007 Jul; 15(7):1253-8. PubMed ID: 17505475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.